NEW YORK, NY—New York City Mayor Eric Adams today signed legislation that will further bolster New York City’s life sciences and biotech sectors by offering a tax incentive for growing biotech companies to create jobs in New York City. The new law builds on significant progress the Adams administration has made to create and attract accessible jobs in life sciences and delivers on a key recommendation to invest in the sector from Mayor Adams and New York Governor Kathy Hochul’s “New' New York: Making New York Work for Everyone” plan.
“Employing more than 20,000 New Yorkers and counting, biotech and life sciences are critical to the success of working people in New York City,” said Mayor Adams. “Our city continues to drive innovation, and with this legislation, we are expanding research, discovery, startups, and more to tap into our city’s talented workforce. I am proud to sign this important legislation that will make the smart investments that pave the way for new scientific breakthroughs and deliver real economic mobility for diverse New Yorkers and their families.”
“As described in the ‘New’ New York plan, New York City must continue to invest in future-focused sectors where we have a competitive advantage and that is exactly what we are doing with the reinstatement of the Biotech Tax Credit,” said Deputy Mayor of Housing, Economic Development, and Workforce Maria Torres-Springer. “Today's legislation sends one message loud and clear: if you are starting or growing a life sciences company, you should do it in New York City because we are invested in your success.”
“A key recommendation from the ‘New’ New York plan, this tax credit will make it easier to attract and retain life sciences startups in New York City — cementing ourselves as a global leader for innovation,” said New York City Economic Development Corporation (NYCEDC) President & CEO Andrew Kimball. “The biotechnology industry is a growing sector throughout New York City, employing over 20,000 New Yorkers. With a goal to double this number in the next 10 to 15 years, creating more high-wage, high-growth jobs for New Yorkers, this industry remains vital in New York City's economic footprint.”
Intro. 1070 - A— sponsored by New York City Councilmembers Jennifer Gutiérrez and James F. Gennaro — creates a tax credit for biotech companies with a capped annual benefit of $3 million to target-growing startups. This bill would renew lapsed tax credits against the General Corporation Tax, the Unincorporated Business Tax, and the Corporate Tax of 2015 and be allowed between January 1, 2023 and January 1, 2026.
The New York City metro area is the country’s leading regional life sciences hub, with nearly 150,000 jobs and 5,100 businesses, generating over $23 billion in wages last year. Last month, Mayor Adams and Governor Hochul unveiled the Science Park and Research Campus (SPARC) Kips Bay Master Plan for this first-of-its-kind life sciences career and education hub that will anchor the city’s industry. New York City was also recently selected by the Chan Zuckerberg Initiative to be the home of a new biomedical research hub in New York City that will leverage a nearly $300 million public-private investment to drive collaboration between leading research institutions and solve significant scientific challenges.
Through the EDC’s LifeSci NYC — a $1 billion initiative — the City of New York is on track to create 1,000 companies and 40,000 jobs, unlock 10 million square feet of wet- and dry-lab real estate, and generate billions of dollars in economic impact over the next 15 years. Since taking office, Mayor Adams has invested $27 million for new life sciences facilities for the City College of New York and Mount Sinai Health System, a new center for sustainability-focused biotech at the Brooklyn Navy Yard, and supported the opening of Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai’s Center for Engineering and Precision Medicine on Manhattan’s West Side.
“In my role as chair of the City Council’s Committee on Technology, and as a Council Member representing the third largest Industrial Business Zone in the city, I understand how reviving the biotechnology tax credit is pivotal in solidifying New York City's status as a premier hub for biotech innovation,” said New York City Councilmember and Chair of the City Council’s Committee on Technology Jennifer Gutiérrez. “By reinstating this tax credit, we will be able to stimulate growth in this essential manufacturing sector by fostering investment, offering incentives to qualified emerging technology companies, and paving the way for new job opportunities. With these initiatives, we are determined to establish New York City as a leader in the field of biotechnology and protect and strengthen our manufacturing zones.”
“The biotechnology tax credit demonstrates the Adams administration’s dedication to fostering innovation and economic growth in future-focused sectors,” said “New” New York Executive Director B.J. Jones. “This initiative will help further cement New York's position as a global leader in creating high-paying, sustainable careers within the life sciences industry.”
“As a homegrown Brooklyn-based biotech company creating jobs and operating the only sterile biomanufacturing facility of its kind in New York City's five boroughs, this bill will bolster the region's emerging biotech ecosystem while helping companies like Cresilon continue attracting and retaining talent, creating high-paying jobs, and bringing innovation to market,” said Cresilon CEO & Co-founder Joe Landolina.
“Thanks to a powerful combination of public sector support and public-private investment, New York City’s life sciences industry has grown dramatically over the past decade,” said Maria Gotsch, president and CEO, The Partnership Fund for New York City. “The reinstatement of the Biotech Tax Credit will help ensure continued growth of New York’s life sciences sector, which will simultaneously foster both valuable scientific innovation and economic development that benefits all New Yorkers.”
“The biotech tax credit is vital to ensuring the continued growth of New York as a national leader in life sciences,” said NewYorkBIO CEO Jennifer Hawks Bland. “This crucial tax credit will help create job opportunities, advance critical research, and continue to provide tremendous economic impact to our city. New York’s life science community is rich with startup companies and this tax credit will allow them to grow and thrive into the future. Today’s bill signing is an acknowledgement of New York’s continued advancements in the life sciences industry, and I look forward to witnessing the growth associated with this investment.”
About NYCEDC
New York City Economic Development Corporation is a mission-driven, nonprofit organization that works for a vibrant, inclusive, and globally competitive economy for all New Yorkers. We take a comprehensive approach, through four main strategies: strengthen confidence in NYC as a great place to do business; grow innovative sectors with a focus on equity; build neighborhoods as places to live, learn, work, and play; and deliver sustainable infrastructure for communities and the city's future economy. To learn more about what we do, visit us on Facebook, Twitter, LinkedIn, and Instagram.
Explore Press Releases
